---

Overview: Versatility of curcumin in management of diabetic retinopathy

Full Text PDF Share on Facebook Share on Twitter

---

Review Article

Author Details : Layba Sayyad, Amit Kakad*, Hemant Raut, Savita Jagtap, Amruta Sonawane, M.R.N Shaikh, Atul Bendale

Volume : 10, Issue : 3, Year : 2023

Article Page : 144-149

https://doi.org/10.18231/j.ijpca.2023.026

Suggest article by email

Get Permission

Abstract

Introduction: On a worldwide scale, the diabetic retinopathy (DR) is listing the primary causes of the loss of sight in the individuals. The main reason behind the occurrence of DR is diabetes mellitus (DM) and diabetic macular edema (DME). Diabetic retinopathy have some types of it i.e Non- proliferative diabetic retinopathy (NPDR) and Proliferative diabetic retinopathy (PDR). Where NPDR is an initial stage and PDR is the severe stage where the person loss the eye sight due to various factors which causes changes in the retinal micro vascularisation.
Materials and Methods: Use of Curcumin in Diabetic Retinopathy may help as a treatment and preventive action for all the stages of DR with its active constituent in various ways. We are focusing on some highlights of curcumin as an active drug to prevent and management of the DR.
Results and Conclusions: As the given review presenting the versatility of natural source of medicine like a curcumin can be the best choice of drug for diabetic retinopathy due to its various effects like protect the loss of retinal ganglionic cells, neuroprotective effect by inhibiting oxidative damage to microglia, also act as anti- inflammatory agent, anti VEGF agent, a recognized PPAR-gamma agonist. Hence, In future Curcumin can be preferably useful for management of all the stages involved in Diabetic Retinopathy.

Keywords: Diabetic retinopathy, Diabetic macular edema, Curcumin, Proliferative & Non-proliferative.

How to cite : Sayyad L, Kakad A, Raut H, Jagtap S, Sonawane A, Shaikh M, Bendale A, Overview: Versatility of curcumin in management of diabetic retinopathy. Int J Pharm Chem Anal 2023;10(3):144-149

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.